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As a part of a drug development program to discover novel therapeutic and more effective palladium (Pd) based anticancer
drugs, a series of water-soluble Pd complexes have been synthesized by interaction between [Pd (phen)(H
2
O)
2
(NO
3
)
2
] and
alkylenebisdithiocarbamate(al-bis-dtc) disodium salts. This study was undertaken to examine the possible cytotoxic effect of
three novel complexes (0.125–64 𝜇g/mL) on human gastric carcinoma (AGS), esophageal squamous cell carcinoma (Kyse-30), and
hepatocellular carcinoma (HepG2) cell lines. The cytotoxicity was examined using cell proliferation and acridine orange/ethidium
bromide (AO/EB) assay. In order to examine the effects of new Pd(II) complexes on cell cycle status, we performed cell cycle
analysis.The complexes were found to have completely lethal effects on the cell lines, and the half maximal inhibitory concentration
(IC50) values obtained for the cell lines were much lower in comparison with cisplatin. We demonstrated that the three new Pd(II)
complexes are able to induce G2/M phase arrest in AGS and HepG2; in addition, the Pd(II) complexes caused an S phase arrest
in Kyse-30 cell line. Our results indicate that newly synthesized Pd(II) complexes may provide a novel class of chemopreventive
compounds for anticancer therapy.
1. Introduction
Cancer is a major public health problem in the world and
more patients are afflicted with gastrointestinal cancer [1].
According to GLOBOCAN 2008 [2], there are increased
incidence rates of the esophageal [3], gastric [4, 5], colon
[6, 7], and hepatic [8, 9] cancers. In the world, about 12.7
million cancer new cases and 7.6 million cancer deaths are
estimated to have occurred [2]. A substantial proportion
of the cancer morbidity could be prevented through early
detection and treatments, which renders the quest for highly
effective antineoplastic agents [6].
Cisplatin is one of the most successful anticancer com-
pounds that have been used clinically for more than 40
years. It is commonly used to treat several human cancers
such as testicular [10] and ovarian [11] cancers and also it is
widely employed for treating bladder [12], cervical [13], head
and neck [14], esophageal [15], and nonsmall cell lung [16]
cancers.
The biological activity of cisplatin cytotoxicity involves
the binding of the drug to DNA and non-DNA targets
and inhibits transcription and DNA replication that finally
leads to apoptosis, necrosis, or both of them. The main
site of cisplatin attack to DNA is N7 atoms of guanine
and adenine located in the major groove of the double
helix [17]. Furthermore, DNA is not the only target for
platinum(Pt) complexes, but many other cell components,
including glutathione, methionine, and other S-containing
biomolecules, can play this role [18–20]. Cisplatin resistance
is a mechanism that includes decreased drug accumulation
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in cancer cells, inactivation by thiol containing biomolecules
(glutathione), and enhanced repair of DNA damage [21–23].
Therapeutic use of cisplatin is limited due to its side effects
such as ototoxicity, nausea, nephrotoxicity, and gastrointesti-
nal and bone marrow toxicity as well as resistance to this
drug. Recently, second-generation cisplatin analogues such as
oxaliplatin, satraplatin (JM216), and LA-12 are described to
have hepatotoxicity and nephrotoxicity milder than cisplatin
[24]. Most anticancer compounds are ineffective in the
treatment of malignant cancers; therefore, much attention
has been focused to find more effective and less toxic com-
plexes than the existing pharmaceuticals. Thus, attention has
turned to other Pt group elements (Pd, ruthenium, iridium,
rhodium, and osmium) and novel design strategy of metal
complexes containing N and S donor ligands such as sodium
diethyldithiocarbamate [25–29].
The Pd complexes display moderate activities; until now,
none has yet been proven to be effective in patients. Recently,
some new Pd(II) and P(II) complexes have been synthesized
to combine anticancer activity and reduce toxic effects of
cisplatin [30]. More recently, we have been studying some
diimine Pt(II) and Pd(II) complexes of dithiocarbamate
derivative as potential anticancer agents [31].
In the present work, three novel Pd(II) complexes
with a dithiocarbamate(dtc) with the formulas (complex
1 = 𝜇 − 1, 3-propylene bis(dithiocarbamate) bis(1,10-phe-
nanthroline Pd(II)) nitrate), (complex 2 = 𝜇 − 1, 4-butylene
bis(dithiocarbamate) bis(1,10-phenanthroline Pd(II))
nitrate), and (complex 3 = 𝜇 − 1, 8-octylene bis(dithiocar-
bamate) bis(1,10-phenanthroline Pd(II)) nitrate) have been
synthesized and characterized. Previously, three Pd(II)
complexes of M(2,2󸀠-bipyridine) (morpholine dithiocar-
bamate) NO
3
Pd(II) complexes, 1,10-phenanthroline hexyl
dithiocarbamatopalladium (II) nitrate [32], and 𝛼-diimine
platinum(II) and Pd(II) dithiocarbamate complexes [31]
have been synthesized and characterized by good anticancer
activity. However, dithiocarbamate complexes of metals
could be more interesting and they display cytotoxic
properties [30].Thus, in this study, we report the cytotoxicity
of three palladium(II) complexes with dithiocarbamate
ligands and the effect of hydrocarbon chain lengths
(propylene, butylene, and octylene) in the structure of
these complexes on the anticancer activity compared to
cisplatin. The Pd(II) complexes are expected to bind DNA
by intercalation [33], a mechanism different from that of
interaction of cisplatin with DNA. Metal complexes that
contain 1,10-phenanthroline have been known to have
effective anticancer activity and also to be intercalated
between the DNA base pairs [34–36].
Therefore, since several reports have represented the fact
that Pd(II) complexes containing dithiol group have low side
effects especially on the kidney [30] and based on the chemo-
preventive cytotoxicity of the three novel Pd(II) complexes
and also chemosensitivity of esophageal, gastric, and liver
cancers, we have decided to investigate the cytotoxicity of
these complexes against gastrointestinal cancer cell lines of
AGS, KYSE-30, and HepG2.
2. Material and Methods
2.1. Culture of Cell Lines. The cell lines used in this study
included AGS, HepG2, and KYSE-30. The cell lines were
obtained from the National Cell Bank of Iran (NCBI, Pasteur
Institute of Iran, Tehran).The cells were maintained in RPMI
1640 (Cat. number 51800-035, Gibco, UK) medium supple-
mented with 10% heat-inactivated fetal bovine serum (FBS;
Cat. number 10270-106, Gibco, UK), 2mM L-glutamine,
penicillin, and streptomycin.The cells were incubated at 37∘C
in a humidified atmosphere with 5% CO
2
until they reached
70–80% confluence. Then, the cells were detached by 0.25
(w/v) trypsin and 0.02 (w/v) ethylenediaminetetraacetic acid
(EDTA) and were then plated in a 96-well for cytotoxicity
assessment.
2.2. Chemicals. A water soluble series of newly synthesized
Pd(II) complexes of formula [(phen) Pd (𝜇-al-bis-dtc)
Pd(phen)](NO
3
)
2
(where alkylenebisdithiocarbamate, al-bis-
dtc = propylenebisdithiocarbamate (pn-bis-dtc, 1); butylene-
bisdithiocarbamate (bu-bis-dtc, 2); and octylenebisdith-
iocarbamate (oc-bis-dtc, 3) and phen = 1,10-phenanthroline)
have been synthesized similar to the procedure outlined
by Islami-Moghaddam et al. [25], by interaction between
[Pd(phen)(H
2
O)
2
](NO
3
)
2
] and alkylenebisdithiocarbam-
ate(al-bis-dtc)disodium salts. In these binuclear Pd(II) com-
plexes, 1,10-phenanthroline (phen) acts as capping ligand and
al-bis-dtc bridges the two Pd centers. Cisplatinwas purchased
from Merck (232120) and dissolved in dimethyl sulfoxide
and added to the medium at 0.125–32 𝜇g/mL concen-
trations
2.3. Cell Proliferation Assay. The effects of the Pd(II) com-
plexes on cell viability were determined using 3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay [37]. The AGS, Kyse-30, and HepG2 cells were plated
at a density of 1 × 104 cells per well in 200 𝜇L medium and
incubated overnight; next, the medium was exchanged
with 0.125–64𝜇g/mL of three new Pd(II) complexes and
indicated concentration of cisplatin in FBS-free RPMI 1640
medium. Afterwards, plates were incubated for 24 and
48 hrs. Then, the supernatant was removed and the MTT
solution (5mg/mL in PBS, 20𝜇L, Sigma, M2128) was added
to each well. Plates were incubated again for additional 4 hrs
at 37∘C in a 5% CO
2
. The supernatants were removed and
DMSO (200𝜇L) was added to each well. Plates were shaken
for 10min to dissolve the precipitate. The sample absorbance
was read at 540 nm using a BioTek Synergy HT microplate
reader (BioTek Instruments Inc., USA).
2.4. AO/EB Staining. AGS, Kyse-30, and HepG2 cell lines
were seeded in six-well plates at a density of 1 × 103 cells
per well and incubated overnight and then various con-
centrations (0.125–64𝜇g/mL) of the new Pd(II) complexes
were added to each well and were incubated for 72 hrs.
After the incubation, the plates were centrifuged for 5min
(129 g, 1,000 rpm) at 4∘C and were washed with phosphate
buffer saline (PBS). The EB/AO dye mix (100𝜇g/mL of AO
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Table 1: IC50 (𝜇g)∗ values of the complexes on AGS, Kyse-30, and HepG2 cell lines, as determined by MTT (24 and 48 hrs) assay. The
cytotoxic activity of three novel Pd(II) complexes was significantly higher (𝑃 < 0.05) in comparison with cisplatin.
Cell lines AGS Kyse-30 HepG2
24 h 48 h Total IC50 24 h 48 h Total IC50 24 h 48 h Total IC50
Complex 1 0.74 ± 0.11 0.63 ± 0.12 0.68 ± 0.12 0.87 ± 0.11 0.89 ± 0.25 0.88 ± 0.18 1.00 ± 0.01 1.04 ± 0.30 1.02 ± 0.16
Complex 2 0.80 ± 0.04 0.75 ± 0.22 0.78 ± 0.13 1.02 ± 0.20 0.95 ± 0.31 0.98 ± 0.26 1.12 ± 0.10 1.23 ± 0.20 1.17 ± 0.15
Complex 3 1.48 ± 0.46 0.94 ± 0.16 1.2 ± 0.31 1.05 ± 0.23 1.06 ± 0.22 1.06 ± 0.23 1.30 ± 0.15 1.09 ± 0.07 1.19 ± 0.11
Cisplatin 4.40 ± 1.56 3.76 ± 0.3 4.08 ± 0.93 1.79 ± 0.30 2.00 ± 0.46 1.9 ± 0.38 2.07 ± 0.05 2.09 ± 0.15 2.079 ± 0.10
∗Mean values ± standard deviation from experiments.
and 100 𝜇g/mL of EB) was prepared in PBS and 100 𝜇L was
added to each well. Cells were viewed under an inverted
fluorescence microscope (IX 71, OLYMPUS) and pictures
were taken with a digital camera (DP 71, OLYMPUS). Tests
were conducted in triplicate by counting a minimum of 100
total cells each by ImageJ software. Live cells were determined
by the uptake of AO (green fluorescence). EB is only able to
pass through the ruptured membrane of late apoptotic and
necrotic cells. Live and dead apoptotic cells were identified
by perinuclear condensation of chromatin stained by AO or
EB, respectively, and by the formation of the apoptotic bodies.
Necrotic cells were identified by uniform labeling of the cells
with EB (red fluorescence) [38–40].
2.5. Cell Cycle Analysis. Cell cycle phase alterations were
determined by analytical DNA flow cytometry. Briefly, the
cells were seeded in 25 cm2 flasks at a density of 1 × 106
cells. The cells were incubated for 24 hrs with IC50 of the
Pd(II) complexes and control was maintained in RPMI-1640
medium supplemented with 10% FBS. After the treatment,
the DNA content and cell cycle distribution were determined
by flow cytometry.The cells were washed with cold PBS twice
and fixed in 70% ethanol at 4∘C at least 4 hrs. The fixed cells
were centrifuged (300 g, 4∘C, 5min) and washed with cold
PBS and then stained with 4,6-diamidino-2-phenylindole
dihydrochloride (DAPi, 1 𝜇g/mL, Triton X-100 0.1% v/v in
PBS) for 30min at 37∘C in the dark. The stained cells were
then transferred to flow tubes by passing through a 30 𝜇m
nylon mesh filters. Flow cytometric analysis was performed
using a flow cytometer (Partec CyFlow Space, Germany).The
distribution of cells in different cell cycle phases was analyzed
using Partec FloMax software [41].
2.6. Statistical Analysis. Statistical analyses were performed
using SPSS 16.0 software. Statistical differences among treated
and control cells were determined by one-way ANOVA
(analysis of variance) followed by Tukey post hoc comparison
test and mean differences with 𝑃 < 0.05 were considered
statistically significant. Dose response curves and IC50 values
were generated using Sigma Plot10 (Systat Software, CA).
3. Results
3.1. Growth Inhibition Study. The anticancer effects of the
Pd(II) complexes against AGS, HepG2, andKEYSE-30 cancer
cell lines were assessed by MTT assay. Cell viability was
determined using the MTT assay after treatment with the
Pd(II) complexes for 24 and 48 hrs. It was found that the
complexes exhibited cytotoxic effects in a dose dependent
manner. According to the dose response curves, the com-
plexes had strong growth inhibitory effects on AGS, Kyse-30,
and HepG2 cells.
Furthermore, the IC50 values of the complexes were
compared to cisplatin (Table 1). These values for Pd(II)
complexes are much lower as compared to those achieved
for cisplatin reported in this paper. The antitumor activity
varied depending on the cell line type and concentration of
the complexes.The difference between antitumor activities of
the Pd(II) complexes is noticed and, in general, the activities
were the same.The analysis of IC50 values showed that Pd(II)
complexes 1 and 2 were more cytotoxic against AGS, Kyse-30,
and HepG2 cells than complex 3. The best cytotoxic effects
were achieved by the Pd(II) complex 1 (IC50 = 0.68) on AGS
cells (Table 1 and Figure 3).
3.2. AO/EB Staining for Apoptotic Cells. Morphological char-
acteristics of the new Pd(II) complexes induced cell death
were determined by AO/EB staining shown in Figure 2. The
results showed that, after incubation at 0.125–64𝜇g/mL of the
three new Pd(II) complexes for 72 hrs, a series of morpho-
logical changes, including condensation and fragmentation
of chromatin and nucleus and formation of apoptotic bodies,
was observedwhichwas the evidence of apoptosis. In contrast
to the treated cells, viable cells exhibited normal and green
nuclei appearances. After the incubation of AGS, HepG2, and
KEYSE-30 cell lines with the tested compound, the decrease
of cell viability in all experimental series was observed. It was
correlated with the increase of concentration of the Pd(II)
complexes.
3.3. Effects of the Pd Complexes on the Cell Cycle. Flow cyto-
metric analysis demonstrated the growth inhibitory effects
of the complexes on cell cycle progression. The cancer cell
lineswere treatedwith increasing concentrations of the Pd(II)
complexes in complete medium and the effective dose was
determined to be at the concentration close to IC50 values to
obtain significant cell cycle arrest (Figure 4).The percentages
of cells in G0/G1, S, and G2/M phase were calculated using
Partec FloMax software and were shown in Table 2 and
Figure 4. Flow cytometry analysis demonstrated that, with
the IC50 values of the complexes, the population of AGS and
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Figure 1: The schematic structure of Pd(II) complexes (complex 1: 𝑛 = 3, complex 2: 𝑛 = 4, and complex 3: 𝑛 = 8).
Table 2: The Pd(II) induced cell cycle arrest. The cell cycle progression blockage was seen in G2-M after 24 hrs of treatment with the IC50 of
the Pd(II) complexes.
AGS Kyse-30 HepG2
G0-G1% S% G2M% G0-G1% S% G2M% G0-G1% S% G2M%
Control 53.85 ± 1.95 21.27 ± 3.50 24.88 ± 2.20 54.39 ± 1.32 16.6 ± 1.59 29.01 ± 1.83 55.97 ± 0.4795 16.35 ± 0.99 27.68 ± 1.86
Complex 1 50 ± 1.44 12.15 ± 0.59 37.84 ± 1.66a 53.01 ± 3.48 23.92 ± 0.26a 22.4 ± 3.16 52.04 ± 3.06 11.39 ± 4.84 36.57 ± 2.76a
Complex 2 51.24 ± 4.65 9.29 ± 0.56 39.47 ± 4.1a 49.98 ± 1.68 21.31 ± 2.13a 28.70 ± 4.98 47.41 ± 4.2 16.68 ± 1.53 35.90 ± 0.97a
Complex 3 52.85 ± 3.77 11.83 ± 6.95 35.31 ± 4.16a 47.96 ± 7.65 25.17 ± 3.52a 26.87 ± 4.13 46.64 ± 4.64 14.19 ± 2.20 39.18 ± 3.15a
The data were pooled from three independent tests and were presented as mean ± STDEV; a <0.05.
HepG2 cells in the G2/M checkpoint was increased signif-
icantly with respect to controls. After 24 hrs, only 24.88%
of untreated AGS cells were in G2/M phase, but 37.84% of
0.68 𝜇g/mL complex 1, 39.47% of 0.78𝜇g/mL complex 2, and
35.31% of 0.94 𝜇g/mL complex 3 treated cells and HepG2
(𝑃 < 0.05 for 36.57%, 35.90%, and 39.18 of complexes-1–3
treated cells with respect to 27.68% of untreated cells) cell
lines were in G2/M phase, respectively. The Pd complexes
caused an S phase arrest in Kyse-30 cell line (measured at 24 h
after treatment), which is not expected since Pd(II) complex
treatment leads to DNAdamage in the G2-Mphase of the cell
cycle (𝑃 < 0.05, for 23.92%, 21.31%, and 25.17% of complexes-
1–3 treated cells, with respect to 16.6%of untreated cells, resp.)
(Table 2 and Figure 4).
4. Discussion
Since the discovery of cisplatin, many new Pt and Pd com-
plexes have been synthesized and evaluated for their possible
cytotoxic activity. However, a few of them were recently
approved and carboplatin and oxaliplatin are being used as
an anticancer drug against several human cancers [21, 42].
Despite the common clinical use of chemotherapeutic agents,
cancer recurrence results in the death of many patients due
to resistance to chemotherapy [23]. Therefore, there have
been many attempts to find complexes which might serve
as less toxic and more effective anticancer drugs [43, 44].
In this study, we synthesized three novel Pd(II) complexes.
The chemical characteristics of the three novel Pd complexes
prompted us to test its potential anticancer activity in vitro. In
fact, due to detoxicant properties of dithiocarbamate against
heavy metal intoxication, it is possible that diethyldithiocar-
bamate reduced the toxicity of these three Pd complexes.
In the present study, we have investigated the cytotoxic
activity and mechanism of action of the three novel Pd(II)
complexes on AGS, HepG2, and KYSE-30 cancer cell lines.
We demonstrated that the new complexes likely behave in a
cytotoxic manner towards the cancer cell lines. On the basis
of the MTT it was shown that the three Pd(II) complexes
exerted stronger cytotoxic influence on the cell line. In
all cell types the IC50 values were lower when compared
to cisplatin. All the cell lines were susceptible. Generally,
at lower concentrations (0.68–1.2 𝜇g), the Pd(II) complexes
induced similar levels of cell death.Therefore, fewer drugs are
required to induce cancer cell death and thus can be tolerated
by patients. Significantly, this study shows the importance
of using a panel of cell lines and Pd(II) complexes. Taking
this into account, we can conclude that the cytotoxic activity
of three novel Pd(II) complexes may also be related to its
geometric structure and size of the molecule (Figure 1).
These data are consistent with those obtained from other
studies, which revealed that diimine Pd(II) complexes of
alkyldithiocarbamate derivatives had anticancer properties
on hepatocellular carcinoma, human ovarian carcinoma, and
human lung adenocarcinoma cancer cells [43].
Recently, different complexes of Pd were synthesized
and their cytotoxic effects were evaluated by our group.
In our previous study, we reported the synthesis and
cytotoxicity of two new metal complexes, namely, 2,2󸀠-
bipyridinebutyldithiocarbamatoplatinum(II) and Pd(II). We
demonstrated that these compounds have strong antitu-
mor activity against chronic myelogenous leukemia cell
line, K562, compared to cisplatin [44]. In another study,
Mansouri-Torshizi et al. revealed that the 𝛼-diimine Pt(II)
and Pd(II) dithiocarbamate complexes had anticancer prop-
erties against K562 and the obtained IC50 values for Pd(II)
(IC50 = 0.007mM,) complexes were lower than those for
cisplatin (IC50 = 0.154mM). Furthermore, the analysis of
the interaction of these novel compounds with CT-DNA
suggests that they can intercalate in DNA [27]. In another
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Figure 2: Photomicrographs of AO/EB-stained control AGS, Kyse-30, andHepG2 cells and the cells treated with IC50 of the Pd complexes (1–
3) for 72 hrs. Representative photomicrographs show live, apoptotic, and necrotic cells treated with the Pd complexes. L: Live; Ap: apoptotic;
N: Necrotic.
study, Ulukaya et al. used new Pd complex ([PdCl(terpy)]
(sac)⋅4H
2
O, (sac = saccharinate, and terpy = 2,2󸀠 : 6󸀠,2󸀠󸀠-
terpyridine) against six prostate cancer cell lines, cancer stem
cells, and primary culture. They found that the Pd complexes
cause DNA damage, cell death, and autophagy [45].
The pattern of cell death was studied by AO/EB. Mea-
surement of AO/EB-stained nuclei showed that the color of
the nuclei of cells treated with the three Pd(II) complexes
was orange or red. The changes in the color of nuclear
chromatin were accompanied by chromatin condensation
and fragmentation, which was also observed after Pd(II)
treatment. The results demonstrated that the new complexes
apply cytotoxic effect via an apoptotic pathway.
The mechanism for the inhibition was further inves-
tigated with cell cycle analysis. Following treatment with
the Pd complex, the AGS and HepG2 cell lines showed
an increase in cells with G2-M DNA content, except in
Kyse-30 cells where they appear to be arrested in S phase.
Overall, it appears that the Pd complex had different effects
on the cell cycle status in various cell lines. In the study
of Mukherjee et al. using Pd complexes with a hydrazone
ligand, prostate cancer (PC-3) cell growth was inhibited at
G2/M phase and apoptosis induced by activation of caspase-
3 [46]. Metal complexes containing 1,10-phenanthroline are
known to produce DNA adducts by intercalation, which
inhibit replication and transcription of DNA [33].
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Figure 3: Representative graphs of AGS, Kyse-30, and HepG2 cells survival after 24 and 48 hrs of cell growth in the presence of the three
Pd(II) complexes.
5. Conclusion
In conclusion, the new Pd(II) complexes are more efficient
in their action on gastric, hepatic, and esophageal cancer
cell lines than cisplatin. Importantly, they also successfully
inhibited the viability of cancer cells at lower concentra-
tions, implying that these Pd(II) complexes may be used
for treatment of cancer. Although we have shown that he
novel Pd complexes mediated cell cycle arrest at G2/M and
S phases. Finally, the understanding of in vivo effects of three
new complexes needs to be investigated further, especially
with animal tumor models to confirm its anticancer and
chemotherapeutic activity in vivo.
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Figure 4: Palladium complex induced cell cycle arrest. AGS, Kyse-30, and HepG2 cell lines were incubated with IC50 of the Pd complexes.
After the incubation for 24 hrs, the cells were harvested and stained with DAPi, and DNA content was assessed by flow cytometry. The
percentage of cells in each phase was plotted as a function of IC50 of the Pd complexes. The progression of AGS (a) and HepG2 (b) cell cycle
was blocked in G2-M when treated with IC50 of three Pd complexes; hence, they stop Kyse-30 cell cycle progression in the S phase (c).
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